Cargando…
Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
INTRODUCTION: Baricitinib–remdesivir (BARI-REM) combination is superior to remdesivir (REM) in reducing recovery time and accelerating clinical improvement among hospitalized patients with coronavirus disease 2019 (COVID-19), specifically those receiving high-flow oxygen/noninvasive ventilation. Her...
Autores principales: | Kelton, Kari, Klein, Tim, Murphy, Dan, Belger, Mark, Hille, Erik, McCollam, Patrick L., Spiro, Theodore, Burge, Russel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606629/ https://www.ncbi.nlm.nih.gov/pubmed/34807369 http://dx.doi.org/10.1007/s12325-021-01982-6 |
Ejemplares similares
-
Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States
por: Ohsfeldt, Robert, et al.
Publicado: (2021) -
Inpatient Hospital Costs for COVID-19 Patients in the United States
por: Ohsfeldt, Robert L., et al.
Publicado: (2021) -
Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021) -
Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
por: Etemad, Lida R., et al.
Publicado: (2005) -
Progressive Ulnar Neuropathy due to anomalous Distal Forearm Muscle: Distal Forearm Decompression
por: McCollam, Grace, et al.
Publicado: (2023)